-
Trastuzumab, sold
under the
brand name
Herceptin among others, is a
monoclonal antibody used to
treat breast cancer and
stomach cancer. It is specifically...
-
Trastuzumab emtansine, sold
under the
brand name Kadcyla, is an antibody-drug
conjugate consisting of the
humanized monoclonal antibody trastuzumab (Herceptin)...
-
Trastuzumab deruxtecan, sold
under the
brand name Enhertu, is an antibody-drug
conjugate consisting of the
humanized monoclonal antibody trastuzumab (Herceptin)...
- Pertuzumab/
trastuzumab/hyaluronidase, sold
under the
brand name Phesgo, is a fixed-dose
combination medication to
treat adults with HER2-positive breast...
-
antibody trastuzumab (marketed as Herceptin).
Trastuzumab is
effective only in
cancers where HER2 is over-expressed. One year of
trastuzumab therapy is...
- 2021.
Tucatinib is a
kinase inhibitor indicated in
combination with
trastuzumab and
capecitabine for the
treatment of
adults with
advanced unresectable...
-
authorization from the
European Medicines Agency in
October 2012.
Trastuzumab emtansine (ado-
trastuzumab emtansine or T-DM1,
trade name: Kadcyla,
marketed by Genentech...
-
Trastuzumab/hyaluronidase, sold
under the
brand name
Herceptin SC
among others, is a fixed-dose
combination medication for the
treatment of HER2-overexpressing...
- of
camptothecin with
antineoplastic activity. A
derivative is used in
Trastuzumab deruxtecan. Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz...
- example, a
targeted anticancer agent –
trastuzumab emtansine (antibody-drug
conjugate containing an
antibody trastuzumab chemically linked to a
highly potent...
